Sutro Biopharma (NASDAQ:STRO) Sets New 1-Year High – Still a Buy?

Sutro Biopharma, Inc. (NASDAQ:STRO) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $39.74 and last traded at $37.1620, with a volume of 43157 shares trading hands. The stock had previously closed at $38.39.

Key Stories Impacting Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Lifesci Capital issued a “Strong‑Buy” rating and detailed multi‑year forecasts that are materially less negative than the current consensus, signaling analyst conviction that losses will narrow over time (Lifesci FY2027 -$5.45 vs. consensus -$9.17). This can support buyer interest despite near‑term losses. MarketBeat: Lifesci Capital Estimates
• Neutral Sentiment: Lifesci provided detailed quarter‑by‑quarter EPS forecasts (example highlights: Q1 2026 -$2.78, Q2 2026 -$1.52, Q3/Q4 2026 -$1.34 each) and long‑range EPS for FY2026–FY2030. These numbers give a clearer roadmap for expected cash‑burn and recovery timing but are forecasts rather than confirmed results.
• Negative Sentiment: The firm remains projected to be deeply unprofitable for several years (FY2026 est. -$6.60; FY2028–FY2030 still showing multi‑dollar losses), which sustains downside risk and explains downward price pressure today as investors weigh near‑term dilution and execution risk.

Analyst Upgrades and Downgrades

STRO has been the topic of a number of analyst reports. Leerink Partners started coverage on shares of Sutro Biopharma in a report on Tuesday, April 7th. They set an “outperform” rating and a $38.00 price objective on the stock. Wells Fargo & Company raised shares of Sutro Biopharma from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $8.00 to $27.00 in a report on Tuesday, March 24th. Citigroup reaffirmed an “outperform” rating on shares of Sutro Biopharma in a report on Friday, April 17th. Lifesci Capital raised shares of Sutro Biopharma to a “strong-buy” rating in a report on Friday. Finally, Mizuho set a $50.00 price objective on shares of Sutro Biopharma and gave the stock an “outperform” rating in a report on Thursday, April 30th. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $40.78.

Sutro Biopharma Trading Down 3.3%

The stock’s fifty day moving average is $25.73 and its two-hundred day moving average is $16.52. The company has a market capitalization of $614.76 million, a PE ratio of -1.42 and a beta of 1.63.

Hedge Funds Weigh In On Sutro Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bridgeway Capital Management LLC boosted its holdings in shares of Sutro Biopharma by 232.6% in the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock worth $37,000 after buying an additional 30,000 shares during the last quarter. Invesco Ltd. raised its stake in Sutro Biopharma by 137.8% in the 1st quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after acquiring an additional 53,390 shares during the period. Cerity Partners LLC raised its stake in Sutro Biopharma by 169.9% in the 2nd quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock valued at $75,000 after acquiring an additional 66,372 shares during the period. Qube Research & Technologies Ltd bought a new stake in Sutro Biopharma in the 2nd quarter valued at about $82,000. Finally, State of Tennessee Department of Treasury bought a new stake in Sutro Biopharma in the 4th quarter valued at about $86,000. 96.99% of the stock is owned by hedge funds and other institutional investors.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.